[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-001", "question": "A 71-year-old woman with a dual-chamber pacemaker (DDDR) for sick sinus syndrome presents with episodic dizziness and syncope. Device interrogation reveals normal lead parameters but frequent pacemaker-mediated tachycardia (PMT) episodes terminated by the device's algorithm. However, she continues to report symptoms. Telemetry shows intermittent 2:1 AV block during atrial tracking, with every second P wave falling within post-ventricular atrial refractory period (PVARP). Which programming adjustment will most effectively eliminate symptoms while preserving maximal atrioventricular synchrony?", "options": ["Extend PVARP by 50 ms", "Enable dynamic PVARP extension after premature ventricular contractions", "Reduce upper tracking limit to 120 bpm", "Switch to DDI mode at rest", "Enable atrial preference pacing"], "answer": "B", "answer_index": 1, "explanation": "Dynamic PVARP extension after PVCs prevents retrograde conduction from initiating PMT while preserving atrial tracking during sinus rhythm. Extending PVARP statically (A) would worsen 2:1 block and cause pacemaker syndrome. Reducing upper tracking (C) does not prevent PMT initiation. DDI mode (D) eliminates atrial tracking entirely. Atrial preference pacing (E) is irrelevant to PMT prevention.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To address this patient's symptoms, I need to analyze what's happening with her pacemaker.\n\nThe patient has:\n- Episodic dizziness and syncope\n- Frequent PMT episodes (which the device terminates)\n- Intermittent 2:1 AV block during atrial tracking\n- Every second P wave falls within PVARP\n\nThe key issue appears to be that some atrial signals are falling within the PVARP and not being tracked, creating a 2:1 AV block pattern. This is likely causing her symptoms despite the device's ability to terminate PMT episodes.\n\nOption A (Extend PVARP by 50 ms) would actually worsen the problem by making more P waves fall within the refractory period.\n\nOption B (Enable dynamic PVARP extension after PVCs) would help prevent PMT initiation after PVCs but wouldn't address the 2:1 AV block issue.\n\nOption C (Reduce upper tracking limit to 120 bpm) would limit the maximum ventricular pacing rate, which could prevent the 2:1 block by allowing more time between ventricular events, thus shortening the effective PVARP relative to the atrial cycle length.\n\nOption D (Switch to DDI mode at rest) would eliminate atrial tracking completely, which would prevent PMT but also eliminate AV synchrony.\n\nOption E (Enable atrial preference pacing) would promote atrial pacing slightly above the intrinsic rate, which could help maintain AV synchrony but wouldn't directly address the 2:1 block issue.\n\nThe most effective solution that preserves maximal AV synchrony would be to reduce the upper tracking limit (option C), as this would prevent the 2:1 block pattern while still allowing atrial tracking.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify the most effective disease-modifying intervention for adult-onset leukoencephalopathy with axonal spheroids (ALSP) caused by a CSF1R mutation.\n\nALSP is a rare, progressive white matter disease caused by mutations in the CSF1R gene, which encodes the colony-stimulating factor 1 receptor. This receptor is critical for microglial development and function.\n\nAmong the options:\n\nA. Intravenous immunoglobulin - While sometimes used for neuroinflammatory conditions, there's limited evidence for efficacy in ALSP.\n\nB. Oral cyclophosphamide - An immunosuppressant with no established benefit in ALSP.\n\nC. Allogeneic hematopoietic stem cell transplantation (HSCT) - This approach has shown promising results in ALSP by replacing defective microglia precursors with healthy donor cells. Case reports and small series have demonstrated stabilization or improvement of symptoms when performed early in the disease course.\n\nD. Ruxolitinib - A JAK inhibitor without established efficacy in ALSP.\n\nE. Supportive care with donepezil - This provides symptomatic management of cognitive symptoms but is not disease-modifying.\n\nBased on current evidence, allogeneic HSCT has shown the most promising disease-modifying effects when performed early in the disease course, before severe disability develops.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "I need to determine the best immediate pharmacologic intervention for this patient with non-islet cell tumor hypoglycemia (NICTH).\n\nThe patient has:\n- Metastatic hemangiopericytoma\n- Severe hypoglycemia refractory to dextrose infusion\n- Low insulin and C-peptide levels (confirming this is not insulin-mediated)\n- Markedly elevated IGF-2 levels and high IGF-2:IGF-1 ratio\n\nThis presentation is classic for non-islet cell tumor hypoglycemia (NICTH) due to IGF-2 secretion from the tumor. The tumor is producing excess IGF-2, which has insulin-like effects causing hypoglycemia.\n\nLet's evaluate each option:\n\nA. Continuous hydrocortisone infusion - Glucocorticoids are first-line therapy for NICTH as they reduce tumor IGF-2 production, increase gluconeogenesis, and decrease peripheral glucose utilization.\n\nB. Recombinant IGF-1 - Would worsen hypoglycemia by adding more insulin-like activity.\n\nC. Diazoxide - Works by inhibiting insulin secretion, but this patient's hypoglycemia is not insulin-mediated.\n\nD. Octreotide - Primarily used for insulinoma; ineffective in NICTH since the hypoglycemia is not mediated by insulin.\n\nE. Glucagon - May provide temporary glucose elevation but is not effective as a sustained treatment for NICTH.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to identify the condition described and determine what histopathologic feature would differentiate it from usual interstitial pneumonia (UIP).\n\nThe case describes a patient with rheumatoid arthritis on methotrexate who has:\n- Upper lobe-predominant disease\n- Pleural thickening and subpleural consolidation\n- Dense subpleural fibrosis with elastic fiber deposition\n- Minimal inflammation\n- Extension into the pleura\n\nThis clinical and radiographic picture is consistent with pleuroparenchymal fibroelastosis (PPFE), which can be associated with rheumatoid arthritis and drug toxicity.\n\nUIP (the pattern seen in idiopathic pulmonary fibrosis) typically shows:\n- Lower lobe predominance\n- Patchy temporally heterogeneous fibrosis\n- Fibroblast foci\n- Honeycomb change\n- Minimal inflammation\n\nThe key distinguishing feature of PPFE from UIP would be the elastosis involving the visceral pleura and subpleural parenchyma, which is not a typical feature of UIP.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question about severe colchicine poisoning management, I need to consider the evidence for each intervention:\n\nA. Colchicine-specific Fab fragments - These are antibody fragments that bind colchicine and have been developed specifically for colchicine toxicity. They can rapidly reverse colchicine poisoning when administered early, and have demonstrated mortality reduction in severe cases.\n\nB. Granulocyte colony-stimulating factor - While G-CSF may help with neutropenia that develops later in colchicine poisoning, it hasn't been shown to reduce mortality when given within the first 12 hours.\n\nC. Continuous venovenous hemofiltration - Colchicine has a large volume of distribution and significant tissue binding, making it poorly removed by extracorporeal methods. This hasn't shown mortality benefit.\n\nD. N-acetylcysteine - This is primarily used for acetaminophen poisoning and has no established role in colchicine toxicity.\n\nE. Plasma exchange - Like other extracorporeal techniques, this is ineffective for colchicine due to its distribution characteristics.\n\nThe evidence supports that colchicine-specific Fab fragments, when administered early (within 12 hours), have demonstrated mortality reduction in severe colchicine poisoning.\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-006", "question": "A 55-year-old man with severe Barlow's disease undergoes 3D transesophageal echocardiography for mitral valve repair planning. The surgeon asks you to identify the parameter that best predicts durable repair. Which measurement most strongly correlates with successful leaflet coaptation after annuloplasty?", "options": ["Anterior leaflet length >35 mm", "Posterior leaflet thickness >5 mm", "Annular height to commissural width ratio >0.3", "Flail gap distance <10 mm", "Coaptation depth >15 mm"], "answer": "C", "answer_index": 2, "explanation": "Annular height to commissural width ratio >0.3 indicates adequate leaflet tissue and annular dynamics, predicting successful repair. Excessive leaflet length (A) and thickness (B) increase complexity but do not predict success. Flail gap (D) and coaptation depth (E) are important but secondary to annular geometry in Barlow's disease where tissue redundancy is the primary pathology.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine which parameter best predicts durable mitral valve repair in Barlow's disease, I need to consider the anatomical factors that influence successful leaflet coaptation after annuloplasty.\n\nBarlow's disease is characterized by myxomatous degeneration with excess leaflet tissue, multi-segment prolapse, and annular dilatation. For successful repair, achieving proper leaflet coaptation is essential.\n\nLet's analyze each option:\n\nA. Anterior leaflet length >35 mm - While anterior leaflet length is important, extreme length can actually complicate repair.\n\nB. Posterior leaflet thickness >5 mm - Increased thickness may indicate more severe myxomatous changes but isn't a primary predictor of repair success.\n\nC. Annular height to commissural width ratio >0.3 - This measures the \"saddle shape\" of the mitral annulus. A higher ratio (>0.15-0.3) indicates better preservation of the natural 3D annular shape, which is critical for optimal leaflet coaptation and reducing leaflet stress after repair.\n\nD. Flail gap distance <10 mm - While relevant for flail segments, this isn't the strongest predictor for overall repair durability in Barlow's disease.\n\nE. Coaptation depth >15 mm - Deeper coaptation (>15 mm) is actually associated with increased repair failure, not success.\n\nThe annular height to commissural width ratio (AHCWR) is a key parameter surgeons use to predict repair durability, as maintaining the natural saddle shape of the mitral annulus is crucial for optimal valve function after repair.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-007", "question": "A 67-year-old man presents with 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, and gait instability. Polysomnography shows severe sleep fragmentation with complete loss of REM sleep. Anti-IgLON5 antibodies are positive in serum and CSF. Which therapeutic strategy has demonstrated modest symptomatic benefit in this tauopathy-mediated autoimmune disorder?", "options": ["High-dose intravenous methylprednisolone 1 g daily for 5 days", "Plasma exchange every other day for 2 weeks", "Rituximab 1 g IV every 2 weeks for 2 doses", "Combined immunotherapy with steroids, IVIG, and rituximab", "Trazodone 100 mg nightly for sleep restoration"], "answer": "D", "answer_index": 3, "explanation": "Combined immunotherapy offers modest benefit in IgLON5 disease by targeting both autoimmune and inflammatory components, though tauopathy progression continues. Monotherapy with steroids (A), plasma exchange (B), or rituximab (C) alone has shown minimal efficacy. Trazodone (E) cannot restore lost REM sleep architecture in this neurodegenerative disorder.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question about anti-IgLON5 disease, I need to consider the current understanding of this condition and its treatment options.\n\nAnti-IgLON5 disease is a complex disorder characterized by a unique combination of neurological symptoms including sleep disorders (particularly REM sleep behavior disorder and sleep apnea), bulbar dysfunction, gait instability, and dysautonomia. It has features of both autoimmunity (antibodies against IgLON5) and neurodegeneration (tau deposition).\n\nRegarding treatment:\n- This condition has been challenging to treat, with variable responses to immunotherapy\n- Most case series suggest that aggressive immunotherapy is needed\n- Combined immunotherapy approaches have shown the most promising results in published cases\n- Single-agent approaches (steroids alone, IVIG alone, or plasma exchange alone) typically show limited benefit\n- Sleep symptoms may respond to symptomatic treatment, but this doesn't address the underlying autoimmune process\n\nBased on the literature, combined immunotherapy approaches (option D) have demonstrated the most consistent, albeit modest, benefits in anti-IgLON5 disease. While no treatment is curative, combination therapy targeting multiple aspects of the immune response has shown better outcomes than monotherapy or symptomatic treatment alone.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-008", "question": "A 28-year-old phenotypic female with 46,XY karyotype and complete androgen insensitivity syndrome (CAIS) due to a null androgen receptor mutation presents with hypertension (BP 165/100 mmHg) and hypokalemia (K+ 2.8 mEq/L). Plasma renin is suppressed (<0.5 ng/mL/hr) and aldosterone is elevated (35 ng/dL). Which pharmacologic agent specifically targets the underlying mineralocorticoid excess in this syndrome?", "options": ["Eplerenone 50 mg twice daily", "Spironolactone 100 mg twice daily", "Amiloride 10 mg twice daily", "Dexamethasone 0.5 mg nightly", "Finasteride 5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "In CAIS, non-aromatized androgens directly activate mineralocorticoid receptors, causing hypertension. Spironolactone (B) antagonizes this effect while also blocking residual androgen receptor activity. Eplerenone (A) is less effective at the androgen-mediated mineralocorticoid effect. Amiloride (C) treats symptoms but not the mechanism. Dexamethasone (D) suppresses ACTH but not peripheral androgen production. Finasteride (E) blocks 5-alpha-reductase, irrelevant in CAIS with absent receptor function.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "To answer this question, I need to analyze the patient's presentation and the underlying pathophysiology.\n\nThe patient has:\n- Complete androgen insensitivity syndrome (CAIS) with 46,XY karyotype\n- Hypertension and hypokalemia\n- Suppressed renin and elevated aldosterone\n\nThis presentation suggests mineralocorticoid excess. In CAIS, the androgen receptor doesn't function, but the patient still produces androgens that can be converted to estrogens or other hormones.\n\nLet's evaluate each option:\n\nA. Eplerenone - A selective mineralocorticoid receptor antagonist that blocks aldosterone action\n\nB. Spironolactone - A mineralocorticoid receptor antagonist that also has anti-androgenic effects (which wouldn't be beneficial in CAIS since androgen receptors already don't function)\n\nC. Amiloride - A potassium-sparing diuretic that blocks epithelial sodium channels but doesn't directly target mineralocorticoid receptors\n\nD. Dexamethasone - A glucocorticoid that can suppress ACTH and potentially reduce adrenal androgen production\n\nE. Finasteride - Inhibits 5α-reductase, preventing conversion of testosterone to dihydrotestosterone\n\nSince the patient has mineralocorticoid excess with elevated aldosterone, a mineralocorticoid receptor antagonist would be most appropriate. Between the two options, eplerenone is more selective for the mineralocorticoid receptor without the anti-androgenic effects of spironolactone (which wouldn't be beneficial in this CAIS patient anyway).\n\nThe answer is (A)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "To answer this question, I need to identify the specific condition and determine the best intervention for long-term survival.\n\nThe patient has:\n- Systemic sclerosis\n- Severe pulmonary hypertension (mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU)\n- Lung biopsy showing diffuse capillary proliferation within alveolar septa\n- Failed response to epoprostenol and macitentan\n- WHO Group 1' pulmonary hypertension\n\nThis presentation is consistent with pulmonary veno-occlusive disease (PVOD), a rare subtype of WHO Group 1' pulmonary hypertension. The key findings supporting this diagnosis are:\n- Severe pulmonary hypertension with normal PAWP\n- Diffuse capillary proliferation on lung biopsy\n- Poor response to pulmonary vasodilator therapy\n\nPVOD has a poor prognosis and typically responds poorly to conventional PAH therapies. In fact, vasodilators can worsen the condition by causing pulmonary edema.\n\nFor PVOD associated with systemic sclerosis:\n- Option A (inhaled treprostinil): Not effective for PVOD\n- Option B (selexipag): Not effective for PVOD\n- Option C (immunosuppression): May help underlying systemic sclerosis but not effective for established PVOD\n- Option D (bilateral lung transplantation): The only definitive treatment for PVOD with proven survival benefit\n- Option E (balloon pulmonary angioplasty): Not indicated for PVOD\n\nLung transplantation is the only intervention that has been shown to significantly improve 5-year survival in PVOD.\n\nThe answer is (D)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-010", "question": "A 62-year-old man with chronic type B aortic dissection (diagnosed 3 years ago) presents with massive hemoptysis. CT angiography shows a 7 cm ulcer-like projection in the descending thoracic aorta with active contrast extravasation into the left lower lobe bronchus. He is hypotensive (BP 85/50 mmHg). Which immediate management strategy has the lowest mortality in this aortobronchial fistula complication?", "options": ["Emergent thoracotomy with open surgical repair", "Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage", "TEVAR with adjunctive left subclavian artery revascularization", "Balloon tamponade of the aortic true lumen", "Massive transfusion protocol only"], "answer": "C", "answer_index": 2, "explanation": "Aortobronchial fistula requires emergent TEVAR to seal the rupture. Adjunctive left subclavian revascularization (C) prevents spinal ischemia and reduces perioperative stroke risk compared to coverage alone (B). Open repair (A) carries >80% mortality in this setting. Balloon tamponade (D) is a temporary bridge only. Transfusion alone (E) is futile without definitive hemorrhage control.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "For this patient with an aortobronchial fistula complication of chronic type B aortic dissection presenting with massive hemoptysis and hypotension, I need to determine the most appropriate immediate management with the lowest mortality.\n\nThe patient has:\n- Massive hemoptysis\n- Hypotension (BP 85/50 mmHg)\n- CT evidence of active contrast extravasation from the aorta into the bronchus\n- A 7 cm ulcer-like projection in the descending thoracic aorta\n\nThis is a life-threatening emergency requiring immediate intervention. Let me evaluate each option:\n\nA. Emergent thoracotomy with open surgical repair - This is highly invasive with significant mortality in an unstable patient.\n\nB. Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage - This is less invasive than open repair and can rapidly control bleeding.\n\nC. TEVAR with adjunctive left subclavian artery revascularization - This adds complexity and time to the procedure when immediate control of bleeding is needed.\n\nD. Balloon tamponade of the aortic true lumen - This is a temporary measure that doesn't definitively address the fistula.\n\nE. Massive transfusion protocol only - This doesn't address the source of bleeding.\n\nTEVAR has become the preferred approach for aortobronchial fistulas due to lower mortality compared to open surgical repair, especially in unstable patients. The immediate goal is to control bleeding rapidly with minimal physiologic stress.\n\nThe answer is (B)"}]